PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 27055578-4 2016 Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile. Chlorambucil 144-156 keratin 20 Homo sapiens 83-87 26951237-4 2016 For the frailest patients, CD20 monoclonal antibodies with or without chlorambucil have proven to be efficacious. Chlorambucil 70-82 keratin 20 Homo sapiens 27-31 27055578-4 2016 Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile. Chlorambucil 302-314 keratin 20 Homo sapiens 83-87 27055578-4 2016 Two large randomized trials recently demonstrated that addition of monoclonal anti-CD20 antibodies (obinutuzumab, rituximab, and ofatumumab) to chlorambucil in untreated comorbid patients lead to improvement in complete remission rate, progression-free survival and even overall survival (obinutuzumab-chlorambucil and rituximab-chlorambucil), with acceptable toxicity profile. Chlorambucil 302-314 keratin 20 Homo sapiens 83-87 26489498-4 2015 Rituximab and the newest anti-CD20 antibody obinutuzumab in combination with chlorambucil, as compared with chlorambucil alone, prolonged overall survival in previously untreated patients with significant comorbidities, and the combination of anti-CD20 antibody with chlorambucil has become the standard regimen in this group of patients. Chlorambucil 77-89 keratin 20 Homo sapiens 248-252 25479582-3 2015 In a recent randomized Phase III study of patients with newly diagnosed CLL and coexisting conditions, obinutuzumab, a humanized anti-CD20 glycoengineered type 2 antibody, used in combination with chlorambucil, demonstrated significant improvement in progression-free survival and several other outcome parameters, in comparison to rituximab plus chlorambucil. Chlorambucil 347-359 keratin 20 Homo sapiens 134-138 24098639-0 2013 New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles. Chlorambucil 82-94 keratin 20 Homo sapiens 126-130 24098639-3 2013 In this contribution, we propose a novel therapeutic approach in which relatively high doses of Hydroxychloroquine and Chlorambucil were loaded into biodegradable nanoparticles coated with an anti-CD20 antibody. Chlorambucil 119-131 keratin 20 Homo sapiens 197-201 24098639-8 2013 In vitro and in vivo data showed the ability of anti-CD20 nanoparticles loaded with Hydroxychloroquine and Chlorambucil to increase tumor cell killing in comparison to free cytotoxic agents or Rituximab. Chlorambucil 107-119 keratin 20 Homo sapiens 53-57 24098639-9 2013 These results shed light on the potential of anti-CD20 nanoparticles carrying Hydroxychloroquine and Chlorambucil for controlling a disseminated model of aggressive lymphoma, and lend credence to the idea of adopting this therapeutic approach for the treatment of B-cell disorders. Chlorambucil 101-113 keratin 20 Homo sapiens 50-54